Marc S. Sabatine, MD, MPH is Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), and a Professor of Medicine at Harvard Medical School (HMS).
Dr. Sabatine graduated magna cum laude from Harvard College and received his medical degree magna cum laude from HMS. He did his Internal Medicine residency, Chief Residency, and Cardiology clinical fellowship at the Massachusetts General Hospital (MGH). He received a Master of Public Health degree from the Harvard School of Public Health. Dr. Sabatine is board certified in Internal Medicine and Cardiology and attends in the coronary care units at both BWH & MGH. He is a Fellow of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
As Chairman of the TIMI Study Group, Dr. Sabatine leads an Academic Research Organization whose mission over the past 30+ years has been to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. To that end, Dr. Sabatine has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering, and other pharmacotherapies. A pioneer in the multimarker approach to risk stratification, Dr. Sabatine has several NIH grants supporting the application of proteomics and metabolomics for discovery of novel biomarkers. He has a long-standing interest in pharmacogenetics and has made seminal observations on the ability to use genetics for personalized medicine.
Dr. Sabatine has authored over 200 original research, peer-reviewed articles including in the New England Journal of Medicine, JAMA, and the Lancet. Dr. Sabatine has given Cardiology or Medical Grand Rounds at top academic centers around the world and has authored numerous review articles and book chapters. He is the recipient of multiple honors and awards including the ACC Zipes Distinguished Young Scientist Award and has been inducted into the American Society of Clinical Investigation. He is on the writing committees for several ACC/AHA practice guidelines. He is a Deputy Editor for JAMA Cardiology.
Eugene Braunwald, MD is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and the founding Chairman of the TIMI Study Group at the Brigham and Women’s Hospital.
He served as the first Chief of the Cardiology Branch and as Clinical Director of the National Heart, Lung and Blood Institute, founding Chairman of the Department of Medicine at the University of California, San Diego. From 1972 to 1996 he was Chairman of the Department of Medicine at the Brigham and Women’s Hospital. He was Chief Academic Officer of Partners HealthCare System.
Dr. Braunwald’s early work focused on the control of ventricular function and he was the first to measure both left ventricular ejection fraction and left ventricular dp/dt in patients. His group showed the first neurohumoral defect in human heart failure, defined the pathophysiology of hypertrophic cardiomyopathy and demonstrated salvage of ischemic myocardium following coronary occlusion. They defined myocardial stunning and ventricular remodeling following myocardial infarction. For the past 33 years, as Chairman of the TIMI Study Group, he and his colleagues demonstrated improved patient survival with a patent coronary artery which led to the widely accepted “open artery hypotheses.” They were the first to show the benefit of preventing adverse remodeling of the infarcted ventricle with ACE inhibition. In the PROVE-IT TIMI 2 Trial, in 2004, they demonstrated the benefit of more intensive reduction of LDL in high risk coronary artery patients, which has changed practice guidelines and will favorably affect the lives of millions.
Science Watch listed Dr. Braunwald as the most frequently cited author in Cardiology; he has an H index of 203. Based on his contributions, Dr. Braunwald has received numerous honors and awards including the Distinguished Scientist and Lifetime Achievement Awards of the American College of Cardiology, Research Achievement, and Herrick Awards of the American Heart Association. He is the recipient of twenty-three honorary degrees. Dr. Braunwald was the first cardiologist elected to the National Academy of Sciences of the United States. The living Nobel Prize winners in medicine voted Dr. Braunwald as “the person who has contributed the most to cardiology in recent years”.
Polly Fish is the Director of Operations for the Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women’s Hospital (BWH). Ms. Fish oversees the development and execution of day-to-day operations, strategic planning, and innovative trial management solutions for sponsors and collaborators. Besides her previous business experience, Ms. Fish brings more than 12 years of cardiovascular clinical trial management experience to her position. As a Senior Project Director at TIMI, she successfully led several of TIMI’s largest, international, randomized controlled trials including TRA 2˚P-TIMI 50, PEGASUS-TIMI 54 and most recently DECLARE-TIMI 58.